AzTrials
AzTrials

Range of MotionNCT07648732

Contralateral Neurodynamic Mobilisation Improves Hamstring Flexibility.

A study testing Neurodynamic Hamstring Mobilisation in people with Range of Motion and Neuromuscular Signs and Symptoms, run by University of Salford.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to investigate whether single limb neurodynamic mobilizations increase active knee extension (AKE) range of motion (ROM) of the contralateral limb. 20 healthy participants (10 females and 10 males, age; 20.8+1.7 years, height; 1.7+ 0.1m, weight; 76.7+ 15.4kg). Read more about this study

Who is it for?
Ages 18 to 30 yearsHealthy volunteers can take part
What is being tested?
Neurodynamic Hamstring Mobilisation
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
20 participants
Where
No sites listed yet
Study dates
Dec 2016to Dec 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 30 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Healthy University students
  • Aged 18-30
  • participating in regular physical activity
  • No current lower back pain
  • No current illness
  • No current hamstring injuries.

Who cannot join

  • Participants aged 31 or over
  • Did not partake in regular physical activity or
  • Experienced lower back pain
  • Currently suffering from an illness
  • Currently sustained a hamstring injuries

About this study

Official title: A Randomized Controlled Crossover Trial of Contralateral Limb Neurodynamic Mobilisation on Hamstring Flexibility in Healthy Individuals.

The goal of this clinical trial is to investigate whether single limb neurodynamic mobilizations increase active knee extension (AKE) range of motion (ROM) of the contralateral limb. 20 healthy participants (10 females and 10 males, age; 20.8+1.7 years, height; 1.7+ 0.1m, weight; 76.7+ 15.4kg). AKE was measured pre- and post- intervention and control. The main question it aims to answer are:

It is hypothesized that contralateral neurodynamic mobilization will significantly increase AKE ROM in asymptomatic individuals.

Read more

Participants were allocated sequentially in an alternating order to study groups. This method aims to balance group sizes while simplifying the assignment. AKE was measured immediately before and after the allocated condition. One week later, at the same time of day, participants returned to complete the opposing condition following a standardized washout period to minimize carryover effects between conditions.

  • Completed a neurodynamic mobilisation on the contralateral limb 6x30seconds, 10 second rest between sets.
  • When acting as the control sat quietly for 4 minutes to match the duration of the intervention condition.
Read the detailed description

This study investigates whether unilateral neurodynamic mobilisation produces measurable changes in active knee extension (AKE) range of motion (ROM) in the contralateral limb. Neurodynamic mobilisation techniques are commonly used to influence the mechanical and physiological behaviour of the peripheral nervous system, and previous research has demonstrated that neurodynamic "slider" techniques can acutely increase ipsilateral hamstring flexibility in asymptomatic individuals. However, the potential for contralateral effects, where treatment applied to one limb results in changes in the opposite limb, has not been directly evaluated using this specific mobilisation approach. The present study addresses this gap by examining whether a single session of unilateral neurodynamic mobilisation alters contralateral AKE performance.

The study was conducted using a counterbalanced crossover design consisting of two separate laboratory sessions: a neurodynamic mobilisation session and a control session. Each participant completed both sessions in a randomised order, with a one-week washout period implemented to minimise potential carry-over effects. All sessions were conducted at the same time of day to reduce variability related to diurnal fluctuations in neuromuscular performance.

During the neurodynamic mobilisation session, participants performed an active neurodynamic sliding technique adapted from previously published protocols. The technique was designed to promote excursion of the sciatic nerve without increasing tensile load. Participants were seated at the edge of a plinth in a flexed spinal posture with the hip and knee flexed and the ankle plantarflexed. From this position, they actively extended the cervical spine, extended the knee, and dorsiflexed the foot before returning to the starting position. Movements were paced using a metronome set at 60 beats per minute, with one full cycle of movement performed per beat. The mobilisation consisted of six sets of 30 seconds, separated by 10-second rest intervals, totalling 90 repetitions. The technique was applied only to the right lower limb.

The control session matched the duration of the mobilisation session but involved no movement. Participants remained seated quietly for four minutes following baseline measurement. This allowed comparison between the effects of the neurodynamic intervention and the passage of time alone.

AKE testing was performed immediately before and after each condition. The test was conducted with the participant lying supine, with the hip and knee of the test limb positioned at 90 degrees using a standardised support. Participants were instructed to actively extend the knee as far as possible while maintaining the hip position. Knee angle was measured using a bubble inclinometer placed on the anterior tibial border. Three measurements were taken at each time point, and the average value was used for analysis. All AKE measurements were performed on the contralateral (left) limb, as the mobilisation was applied to the right limb.

Statistical analysis involved a two-by-two repeated measures analysis of variance to examine the interaction between condition (mobilisation vs control) and time (pre vs post). Normality was assessed using the Shapiro-Wilk test. Post-hoc pairwise comparisons were conducted to explore the direction of significant interactions. Effect sizes were calculated using partial eta squared and Cohen's d. Test-retest reliability of the AKE test was assessed using data from the control condition collected one week apart, enabling calculation of the standard error of measurement (SEM) and minimal detectable change (MDC). These values were used to determine whether observed changes exceeded measurement error at both group and individual levels.

Being tested
Neurodynamic Hamstring Mobilisation
Keywords
Slider, Range of Motion, Cross-Education, Neuromuscular System
Medical subject headings
Neuromuscular Manifestations, Wounds and Injuries

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Neurodynamic Hamstring MobilisationOther

    Sciatic Neurodynamic slider performed on the right leg.

Study groups in NCT07648732
Study groupRoleWhat they receive
Neurodynamic GroupExperimentalThe neurodynamic technique was adapted from Castellote-Caballero12. The active neurodynamic sliding technique required the participant to sit on the edge of the bed with their feet off the floor. Participants sat in a slumped position with their thoracic and cervical spine flexed, knees flexed and feet plantar flexed. They then extended their cervical spine, extended their knee and dorsiflexed their foot before returning to the starting position, counting as one repetition. This was performed on the right leg for six sets of 30 seconds with a 10 second rest between sets, using a metronome app (ONYX 3, Apple, California) set at 60bpm. Participants flexed and extended their leg on each metronome beat, completing 90 repetitions in total.
Receives: Other: Neurodynamic Hamstring Mobilisation
Control GroupPlacebo comparatorFollowing an initial active knee extension test measurement, participants in the control condition were instructed to sit quietly for 4 minutes to match the duration of the intervention condition.
Receives: Other: Neurodynamic Hamstring Mobilisation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Active Knee Extension Test

    Data will be recorded three times to then take a mean. Active knee extension test will be performed utilising a bubble inclinometer placed on the participants tibial tuberosity. Standardised hip flexion to 90 degrees as the active knee extension is performed.

    Measured: Baseline (Day 1) and Day 7.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Jun 2026
  2. Study startDec 2016
  3. Primary completionApr 2017
  4. Study completionDec 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07648732
Sponsor's protocol ID
ethics number 1516-280
Status last verified
Jun 2026
First submitted
8 Jun 2026
Last updated
15 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Neurodynamic Hamstring Mobilisation in people with Range of Motion and Neuromuscular Signs and Symptoms, run by University of Salford.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Active Knee Extension Test (time frame: Baseline (Day 1) and Day 7.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jun 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in